
Sign up to save your podcasts
Or


This is the first dedicated peptide deep dive of The Energy Code — and it starts with arguably the most mitochondrial-centric peptide on the board: SS-31 (Elamipretide). Dr. Mike breaks down a new paper showing how SS-31 may protect neurons in Parkinson’s disease by competing with alpha-synuclein at lipid membranes, slowing toxic aggregation, restoring mitochondrial respiration, and even reducing alpha-synuclein cellular entry. You’ll also hear a key caution: SS-31 appears highly protective at moderate doses, but too much may flip the benefit into harm, reinforcing the “dose makes the medicine” rule in mitochondrial pharmacology.
(Educational content only, not medical advice.)
-
Article Discussed in Episode:
Therapeutic Peptide SS-31 Modulates Membrane Binding and Aggregation of α-Synuclein and Restores Impaired Mitochondrial Function
-
Key Quotes From Dr. Mike:
“The future of Parkinson’s therapy may not lie in cleaning up the mess, but rather in providing our neurons with a permanent molecular shield…”
“SS-31 acts as a molecular shield protecting the brain’s energy supply…”
“SS-31 acts as a molecular bouncer, physically evicting alpha-synuclein from lipid membranes…”
“SS-31 substantially prolonged the lag phase of aggregation, essentially stalling the clock on protein buildup.”
“These findings underscore the multifaceted protective role of SS-31 against mitochondrial dysfunction caused by alpha synuclein aggregation... SS-31 reversed this decline with a 10 micromolar dose…”
-
Key Points
-
Episode timeline
-
Dr. Mike's #1 recommendations:
Deuterium depleted water: Litewater (code: DRMIKE)
-
Stay up-to-date on social media:
Dr. Mike Belkowski:
BioLight Labs:
Website
BioLight:
Website
YouTube
By Dr. Mike Belkowski4.8
124124 ratings
This is the first dedicated peptide deep dive of The Energy Code — and it starts with arguably the most mitochondrial-centric peptide on the board: SS-31 (Elamipretide). Dr. Mike breaks down a new paper showing how SS-31 may protect neurons in Parkinson’s disease by competing with alpha-synuclein at lipid membranes, slowing toxic aggregation, restoring mitochondrial respiration, and even reducing alpha-synuclein cellular entry. You’ll also hear a key caution: SS-31 appears highly protective at moderate doses, but too much may flip the benefit into harm, reinforcing the “dose makes the medicine” rule in mitochondrial pharmacology.
(Educational content only, not medical advice.)
-
Article Discussed in Episode:
Therapeutic Peptide SS-31 Modulates Membrane Binding and Aggregation of α-Synuclein and Restores Impaired Mitochondrial Function
-
Key Quotes From Dr. Mike:
“The future of Parkinson’s therapy may not lie in cleaning up the mess, but rather in providing our neurons with a permanent molecular shield…”
“SS-31 acts as a molecular shield protecting the brain’s energy supply…”
“SS-31 acts as a molecular bouncer, physically evicting alpha-synuclein from lipid membranes…”
“SS-31 substantially prolonged the lag phase of aggregation, essentially stalling the clock on protein buildup.”
“These findings underscore the multifaceted protective role of SS-31 against mitochondrial dysfunction caused by alpha synuclein aggregation... SS-31 reversed this decline with a 10 micromolar dose…”
-
Key Points
-
Episode timeline
-
Dr. Mike's #1 recommendations:
Deuterium depleted water: Litewater (code: DRMIKE)
-
Stay up-to-date on social media:
Dr. Mike Belkowski:
BioLight Labs:
Website
BioLight:
Website
YouTube

784 Listeners

365 Listeners

7,212 Listeners

5,000 Listeners

723 Listeners

1,727 Listeners

4,897 Listeners

3,464 Listeners

9,256 Listeners

171 Listeners

1,091 Listeners

1,778 Listeners

841 Listeners

526 Listeners

305 Listeners